Welcome to our dedicated page for Larimar Therapeutics news (Ticker: LRMR), a resource for investors and traders seeking the latest updates and insights on Larimar Therapeutics stock.
Larimar Therapeutics, Inc. (NASDAQ: LRMR) is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, with its lead compound, nomlabofusp, in development as a potential treatment for Friedreich’s ataxia (FA). The Larimar news feed on Stock Titan aggregates the company’s press releases and related coverage so readers can follow key milestones in this rare disease program.
News about Larimar frequently centers on clinical data updates from the ongoing long-term open-label and open-label extension studies of nomlabofusp in FA. The company has reported increases in skin frataxin (FXN) levels with daily subcutaneous dosing, directional improvements in clinical outcome measures such as mFARS, FARS-ADL, 9-Hole Peg Test, and Modified Fatigue Impact Scale, and long-term safety observations including injection site reactions and anaphylaxis events. Larimar also publishes nonclinical findings that describe the mechanism of action and pharmacology of nomlabofusp as an FXN protein replacement therapy.
Another major category of LRMR news involves regulatory interactions and timelines. Larimar has disclosed written recommendations from the U.S. Food and Drug Administration on the safety database needed for its Biologics License Application and the agency’s openness to using skin FXN concentrations as a reasonably likely surrogate endpoint for an accelerated approval pathway. The company regularly issues press releases on these regulatory updates, its participation in the START pilot program, and its targeted timing for a BLA submission seeking accelerated approval.
Investors and followers will also see financial results and capital markets announcements, including quarterly operating and financial updates, underwritten public offerings of common stock, and the use of proceeds to fund nomlabofusp development and other pipeline plans. For a consolidated view of LRMR-related developments—spanning clinical, regulatory, and financing events—this news page provides an organized stream of Larimar’s own disclosures and market-facing communications.
Larimar Therapeutics (NASDAQ: LRMR) reported Q4 and full‑year 2025 results and provided clinical and financing updates. Key items: Breakthrough Therapy Designation for nomlabofusp in Friedreich’s ataxia, topline open‑label data expected Q2 2026, planned BLA submission in June 2026, Phase 3 screening to start Q2 2026, and U.S. launch targeted H1 2027 if approved.
Balance sheet: pro forma cash of $244.5M and projected runway into Q2 2027 after a $107.6M net public offering. Reported full‑year net loss $165.7M; increased R&D investment to support commercialization.
Larimar Therapeutics (Nasdaq: LRMR) announced management will present and hold 1x1 investor meetings at two Miami Beach investor conferences in March 2026.
Presentations: Leerink Partners Global Healthcare Conference on March 10, 2026 at 8:40 AM ET and Citizens Life Sciences Conference on March 11, 2026 at 4:00 PM ET. Replays will be available for 30 days on Larimar’s Events and Presentations page.
Larimar Therapeutics (Nasdaq: LRMR) priced an upsized underwritten public offering of 20,000,000 common shares at $5.00 per share, yielding expected gross proceeds of $100 million before expenses. The underwriters have a 30‑day option for an additional 3,000,000 shares.
The offering is expected to close on or about February 27, 2026. Larimar said net proceeds will support development of nomlabofusp and fund working capital, R&D and commercialization expenses. The offering uses an effective Form S-3 shelf registration (effective May 24, 2024).
Larimar Therapeutics (Nasdaq: LRMR) announced a proposed underwritten public offering of $75 million of common stock and, optionally for some investors, pre-funded warrants, with a 30-day option for underwriters to purchase up to an additional $11.25 million.
Proceeds are intended to fund development of nomlabofusp and for working capital and general corporate purposes. The offering is subject to market conditions; final terms will be in a prospectus supplement filed with the SEC.
Larimar Therapeutics (Nasdaq: LRMR) announced the FDA granted Breakthrough Therapy Designation for nomlabofusp for adults and children with Friedreich’s ataxia (FA). The FDA and company aligned on using skin FXN as a potential surrogate endpoint to support a planned BLA seeking accelerated approval in June 2026.
Topline open‑label study data to support the BLA are expected in Q2 2026, a global Phase 3 will be underway at submission, and a U.S. launch is targeted in H1 2027 if approved.
Larimar Therapeutics (Nasdaq: LRMR) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco from January 12–15, 2026. Management presentation is scheduled for Wednesday, January 14, 2026, 9:00–9:40 AM PST, and the team will participate in 1x1 investor meetings during the conference.
A live webcast will be available at the conference portal and a replay will be posted on Larimar’s Events and Presentations page for 30 days after the presentation.
Larimar Therapeutics (Nasdaq: LRMR) reported Q3 2025 results and program updates for nomlabofusp for Friedreich’s ataxia. Key clinical highlights include 100% of 10 participants achieving skin frataxin (FXN) >50% of healthy median at 6 months and a median mFARS improvement of 2.25 at 1 year versus a median worsening of 1.00 in a FACOMS reference population. Larimar plans a BLA seeking accelerated approval in Q2 2026 and targets U.S. launch in early 2027. Financially, Larimar reported $175.4M cash as of Sept 30, 2025, with runway into Q4 2026.
Larimar Therapeutics (NASDAQ:LRMR) reported positive data from its ongoing long-term open label study of nomlabofusp for Friedreich's ataxia (FA). The study showed that all 10 participants with 6-month data achieved skin frataxin (FXN) levels over 50% of median levels found in healthy volunteers, comparable to levels in asymptomatic carriers.
Key highlights include consistent improvements across 4 clinical outcomes after 1 year of treatment compared to natural history data, with 39 participants receiving at least one dose and 25 currently on daily dosing. However, 7 participants experienced anaphylaxis within the first 6 weeks of dosing, leading to protocol modifications. The company plans to submit a BLA for accelerated approval in Q2 2026.
Larimar Therapeutics (NASDAQ:LRMR), a clinical-stage biotech company, has scheduled a conference call and webcast for September 29, 2025, at 8:00 am EDT to discuss updates on their nomlabofusp clinical development program. The presentation will include data from the ongoing long-term open label study for the treatment of Friedreich's ataxia.
Investors can access the webcast through a provided link or join by phone using the dial-in numbers 1-877-407-9716 (domestic) or 1-201-493-6779 (international) with conference ID 13756144. An archived version of the webcast will be available on Larimar's website after the live event.
Larimar Therapeutics (Nasdaq: LRMR) reported Q2 2025 financial results and provided updates on its nomlabofusp development program for Friedreich's ataxia (FA). The company plans to submit a Biologics License Application (BLA) for accelerated approval in Q2 2026, supported by $203.6 million in pro forma cash providing runway into Q4 2026.
Key developments include: FDA's recommendation for safety database requirements, planned initial data from the 50 mg open label study in September 2025, completion of adolescent PK run-in study with 14 participants, and expansion of the open label study to include children. The company reported a Q2 2025 net loss of $26.2 million ($0.41 per share) compared to $21.6 million in Q2 2024.
Larimar strengthened its position through a $65.1 million public offering in July 2025 and published two peer-reviewed articles supporting nomlabofusp's mechanism of action. Global Phase 3 study sites have been identified with patient recruitment expected to begin later in 2025.